Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19

Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19 The last patient had his/her last visit in MetrioPharm’s trial in COVID-19 on July 28tth Data cleaning and analysis will start subsequently Topline Data expected in Q4 2022   Zurich, July 29, 2022.  MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announced […]

MetrioPharm partakes in EU-wide coordination and collaboration meeting for EU-funded projects conducting clinical trials on COVID-19 therapeutics

MetrioPharm partakes in EU-wide coordination and collaboration meeting for EU-funded projects conducting clinical trials on COVID-19 therapeutics Virtual meeting, April 06, 2022     We are two years into a novel coronavirus pandemic that affects and transforms countless lives worldwide. While considerable progress has taken place over these last years – such as the creation of […]

MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19  

MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19 Zurich, March 02, 2022.   MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announced on the 2nd of March that more than 50% of the number of patients that were planned to be enclosed, have now been enrolled in the Phase II […]

MetrioPharm Signs European Commission Grant Agreement for €7.9 Million

MetrioPharm Signs European Commission Grant Agreement for €7.9 Million European commission funds COVID project iMPact with 7.9 million euros MetrioPharm will receive a total of 7.5 million euros of the provided sum iMPact project aims to research COVID-19 therapies   Zurich, November 24, 2021. MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announces that […]